Endogenous opiates modulate pulsatile luteinizing hormone release in humans

The Journal of Clinical Endocrinology and Metabolism, 52(3), 583-585

DOI 10.1210/jcem-52-3-583 PMID 6780598

Abstract

To test the postulate that endogenous opioid peptides may be involved in the neuroendocrine mechanisms controlling the frequency and amplitude of LH pulses, saline and an opioid receptor antagonist, naloxone, were infused sequentially, each for 6-h intervals, in six normal cycling women during the luteal phase of the menstrual cycle. During naloxone infusion (1.6 mg/h), there was a significant (P less than 0.01) increase in both the frequency and amplitude of LH pulses compared to those in saline controls. FSH pulses were not discernible in individual subjects; however, a significant increment in FSH levels occurred concomitantly with the increase in LH. These data strongly suggest that endogenous opiates, through an inhibition of hypothalamic LRF, participate in the endocrine events leading to the low frequency of episodic LH secretion characteristic of the luteal phase of the human menstrual cycle.

Topics

endogenous opiates LH pulsatile secretion luteal phase, naloxone LH pulse frequency amplitude women, opioid peptides neuroendocrine regulation gonadotropin release, Yen SS Ropert opioid LH pulse modulation, naloxone infusion FSH LH increase luteal phase, endogenous opioid inhibition hypothalamic GnRH pulsatility, opioid receptor antagonist menstrual cycle LH secretion, beta-endorphin regulation luteinizing hormone releasing factor, neuroendocrine control episodic LH secretion women, opioid modulation gonadotropin pulsatility normal cycling women
PMID 6780598 6780598 DOI 10.1210/jcem-52-3-583 10.1210/jcem-52-3-583

Cite this article

Ropert, J. F., Quigley, M. E., & Yen, S. S. (1981). Endogenous opiates modulate pulsatile luteinizing hormone release in humans. *The Journal of clinical endocrinology and metabolism*, *52*(3), 583-585. https://doi.org/10.1210/jcem-52-3-583

Related articles